Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Common Equity (2024 - 2025)

Kairos Pharma's Common Equity history spans 2 years, with the latest figure at $6.3 million for Q4 2025.

  • For Q4 2025, Common Equity rose 32.77% year-over-year to $6.3 million; the TTM value through Dec 2025 reached $6.3 million, up 32.77%, while the annual FY2025 figure was $6.3 million, 32.77% up from the prior year.
  • Common Equity reached $6.3 million in Q4 2025 per KAPA's latest filing, up from $6.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $7.1 million in Q1 2025 to a low of -$2.7 million in Q2 2024.